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Abstract
Although chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) seem to be
opposite entities from a clinical perspective, common initial pathogenic steps have been suggested in both lung
diseases. Emphysema is caused by an elastase/anti-elastase imbalance leading to accelerated elastin degradation.
Elastinolysis is however, also accelerated in the IPF patients’ lungs. The amino acids desmosine and isodesmosine
(DES) are unique to elastin. During the degradation process, elastases liberate DES from elastin fibers. Blood DES
levels consequently reflect the rate of systemic elastinolysis and are increased in COPD. This is the first report
describing elevated DES levels in IPF patients. We also demonstrated that the age-related increment of DES
concentrations is enhanced in IPF. Our current study suggests that elastinolysis is a shared pathogenic step in both
COPD and IPF. Further investigation is required to establish the relevance of accelerated elastin degradation in IPF
and to determine whether decelerating this process leads to slower progression of lung fibrosis and better survival
for patients with IPF.
To the Editor,
Although chronic obstructive pulmonary disease (COPD)
and idiopathic pulmonary fibrosis (IPF) seem to be opposite
entities from a clinical perspective, they often coexist in the
same patient [1], and shared pathogenic mechanisms have
been suggested between these two lung diseases [2]. It is
generally thought that emphysema is caused by an elastase/
anti-elastase imbalance leading to accelerated elastin deg-
radation. Elastinolysis, however, is also accelerated in the
lungs of patients with IPF [3]. Similarly, matrix metallopro-
teinases are elastases that play a pivotal role in COPD but
are also implicated in the pathogenesis of IPF [4].
The elastin precursor tropoelastin is mainly produced
perinatally [5]. Tropoelastin monomers are subsequently
aligned, and the resulting tropoelastin polymers are
crosslinked into durable elastin fibers by the enzyme
lysyl oxidase [5]. This crosslinking process gives rise to
the amino acids desmosine and isodesmosine (DES),
which are unique to mature elastin [5]. During the elas-
tin degradation process, elastases liberate DES from elas-
tin fibers [6]. Consequently, plasma (p)DES levels reflect
the rate of elastinolysis. pDES levels are increased in
COPD patients [7], and DES concentrations are also
elevated in bronchoalveolar lavage fluid of patients with
IPF [3]. However, data regarding pDES in IPF are lack-
ing. Huang et al. recently demonstrated that elastin
degradation accelerates during ageing in subjects with or
without obstructive lung disease, but that this age-
related DES increment is amplified in patients with
COPD [8]. Whether this also holds true for patients with
IPF is currently unknown.
By analogy to COPD, we hypothesized that pDES
levels would be elevated and that the age-related pDES
increment would be enhanced in IPF patients compared
to controls with no lung disease.
pDES levels were measured by liquid chromatography
tandem-mass spectrometry in 154 IPF patients from
Maastricht (59 subjects, 30 males, 59±11 years, 11 active
smokers, 44 never smokers, 4 former smokers), from
Nieuwegein (20 subjects, 18 males, 66±9 years, 16
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former smokers, 4 never smokers) and from Ann Arbor
(75 subjects, 56 males, 67±7 years, 38 former smokers,
37 never smokers) as previously described [8, 9]. IPF
was diagnosed by a multidisciplinary team of experts ac-
cording to international guidelines [10]. For each pDES
measurement in an IPF patient, a virtual age-matched
pDES value was calculated using published pDES equa-
tions: non-smoking controls (50+2.91*age ng/L), smok-
ing controls (70+3.12*age ng/L) and COPD patients (50
+6.57*age ng/L) [8]. pDES levels were also measured in
142 patients with moderate to severe COPD (121 males;
68±9 years) and 84 controls (29 males; 46±13 years).
Correlations between forced vital capacity (FVC) and
pDES values were investigated. Analysis of covariance
(SPSS version 24) was used to compare pDES levels be-
tween groups, adjusted for age. Data are presented as es-
timated marginal means ± standard error of the mean.
A significant correlation was found between age and
pDES (p<0.0005). The equation for the pDES regression
line in IPF patients was 76 (95% CI -117–270)+6.76
(95% CI 3.75–9.77)*age (ng/L). Significantly higher pDES
levels were found in IPF patients (507±8 ng/L) compared
to age-adjusted reference values of non-smoking controls
(236±8 ng/L, p<0.0005), of smoking controls (269±8 ng/L,
p<0.0005) and of COPD patients (469±8 ng/L, p=0.001;
Fig. 1a and 1b) [8]. No significant differences in pDES
levels were found between the three IPF cohorts
(p=0.785). pDES levels were 509±24 ng/L in IPF patients
from Maastricht, 481±40 ng/L in IPF patients from
Nieuwegein, and 512±21 ng/L in IPF patients from Ann
Arbor. Significantly higher pDES levels were found in both
COPD (457±23 ng/L, p=0.006) and IPF patients
(p<0.0005) compared to controls (337±32 ng/L). No sig-
nificant differences in pDES levels were found between
IPF and COPD patients (p=0.2). FVC data at baseline were
available from the Nieuwegein and Ann Arbor cohort; no
significant correlation was found between pDES levels and
%FVC of predicted at baseline (p=0.3). FVC follow-up
data were available from the Nieuwegein cohort; a
significant correlation was demonstrated between pDES
levels and the change in %FVC of predicted per year
(p=0.02).
We have demonstrated elevated pDES levels in IPF pa-
tients from three independent cohorts compared to
smoking and non-smoking controls and COPD patients.
We also found amplified age-related DES increment in
IPF similar to what was previously described for COPD
[8]. We also demonstrated a correlation of pDES with
lung function decline.
The strong effect of age on pDES levels in IPF patients
once again stresses the importance of taking age into ac-
count as a covariate when interpreting concentrations of
this biomarker. It has previously been noted that pDES
increases both in controls and COPD patients during
ageing, but that the gain factor due to age is much
higher in the latter [8]. We now demonstrate that age-
related pDES increment is also amplified in IPF, which
corroborates to the acceleration of ageing processes ob-
served in patients with IPF [11].
It has previously been demonstrated that pDES levels
are related to emphysema progression in COPD patients
with alpha-1 antitrypsin (AAT) [12]. Based particularly
on the observation that emphysema is often present in
lungs of IPF patients [1], we suspect there are similar-
ities in the pathogenesis of lung fibrosis and emphysema.
Fig. 1 Circulating desmosine levels in IPF patients, based on
measurements, and in three other groups, based on virtual age-
matched controls calculated with Huang et al.’s equations: non-
smoking controls (50 + 2.91*age ng/L; blue), smoking controls
(70 + 3.12*age ng/L; green) and COPD patients (50 + 6.57*age ng/L;
red) [8]. a) Boxplots showing blood desmosine levels (5th percentile, 1st
quartile, median, 3rd quartile, and 95th percentile). Significantly higher
blood desmosine levels were found in IPF patients compared to
smoking or non-smoking controls and COPD patients. b) Scatterplot in
which the black dots represent circulating desmosine measurements
and the black line the deduced equation line in IPF patients
(76 + 6.76*age ng/L).
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Our present results of accelerated elastin degradation in
IPF patients –with pDES concentrations at least as high
as previously described in COPD– may be interpreted as
circumstantial evidence that elastinolysis could be a
shared pathogenic step between COPD and IPF. Inter-
estingly, data from an animal model have suggested a
decisive role for elastin metabolism in the divergence be-
tween lung fibrosis and emphysema during the patho-
logical sequelae of lung injury [2]. Whereas intratracheal
administration of cadmium chloride caused fibrosis in
hamsters’ lungs, combining this toxin with an inhibitor
of the elastin crosslinker lysyl oxidase led to emphysema
[2]. Additional studies are needed to unravel which spe-
cific steps of elastin metabolism are involved in IPF
pathogenesis.
Previous research has mainly focussed on pDES as a
biomarker of systemic elastin degradation in COPD [13].
Our present findings of even higher pDES in IPF pa-
tients than in patients with COPD also justifies explor-
ing the role of this biomarker in IPF. When interpreting
pDES levels in patients with COPD, it is important to
realize that elastin degradation in COPD is not only ac-
celerated in the lungs but also in other dynamic tissues
such as arteries and skin [14]. In contrast to the severity
and progression of emphysema, the burden of coronary
artery calcification (CAC) has been associated with
pDES levels in COPD patients with normal AAT levels
[7], which might indicate that arteries are the main con-
tributors to pDES in this patient group. CAC is also
prevalent in IPF patients [1], and future studies are
therefore needed to assess whether pDES also relates to
CAC in IPF. The pulmonary arteries may also be a po-
tential source of circulating elastin fragments in IPF pa-
tients, given that pDES levels are elevated in patients
with pulmonary arterial hypertension and that pulmon-
ary hypertension is another common comorbidity of IPF
[1, 15]. Furthermore, DES seems to be a predictor of
mortality in COPD and cystic fibrosis [7, 16]. It is there-
fore also relevant to assess the prognostic value of pDES
for survival in patients with IPF.
We regard deceleration of elastin degradation as a po-
tential attractive novel therapeutic target in COPD. This
intriguing new concept was illustrated by a recently pub-
lished post hoc study in which AAT augmentation therapy
resulted in a decrease of pDES levels in AAT deficient
COPD patients [12]. In IPF, the treatment landscape has
shown positive changes following the introduction of the
two anti-fibrotic drugs pirfenidone and nintedanib [10].
Although the complex and pleiotropic properties of these
agents have not been precisely unravelled, their mecha-
nisms of action seem to be quite different. Whether inhib-
ition of elastin catabolism is a relevant therapeutic effect
of these anti-fibrotics is currently unknown. Additional
studies are needed to assess whether pirfenidone and/or
nintedanib have effects on pDES levels. Furthermore, it is
important to study whether modifications in the rate of
elastin degradation run parallel to changes in the disease
course of patients with IPF. In other words, whether
decelerating and accelerating elastin degradation in IPF
translates into slower and faster disease progression,
respectively. This may be suggested by the association we
found between baseline pDES levels and FVC decline. We
might speculate about validating combinations of IPF
biomarkers to make a more educated choice between
pirfenidone and nintedanib in individual patients, based
on expected efficacy rather than adverse side effects, as is
the current practice [10]. Future studies have to reveal
whether there may be a role for pDES in such a panel.
In summary, this is the first study describing elevated
pDES levels in IPF patients, which were even higher
than in COPD patients. We also demonstrated that the
age-related increment of pDES concentrations is
enhanced in IPF. Additional studies are needed to estab-
lish the relevance of accelerated elastin degradation in
IPF and to determine whether decelerating this process
translates into slower progression of lung fibrosis and
better survival for patients with IPF.
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